clock menu more-arrow no yes

Subscribe to Antivirus: a weekly newsletter on COVID-19 research

Straight to your inbox

By Mary Beth Griggs
Antivirus Newsletter

Antivirus Newsletter

What we're learning about the coronavirus, notable news from the vaccine and treatment fronts, and stories that remind us that there's more to the case counts than just numbers. Subscribe to the newsletter here.

US COVID-19 data has never been good enough

By Nicole Wetsman

The unsettling uncertainty of a breakthrough case

By Nicole Wetsman

Vaccine carrots only got us so far — now, it’s time for sticks

By Nicole Wetsman

Communication around masks is still terrible

By Nicole Wetsman

The stakes for fighting misinformation are life and death

By Nicole Wetsman

Health risk

The Olympics are still stuck in 2020

By Nicole Wetsman

Rimac takes over Bugatti from VW in powerhouse electric supercar deal

By Andrew J. Hawkins
40 comments / new

Full approval could make the difference for the US COVID-19 vaccine campaign 

By Nicole Wetsman

Who needs COVID-19 boosters?

By Nicole Wetsman

The slow transitions of a lingering pandemic

COVID-19 is ebbing in some parts of the world

By Mary Beth Griggs

Pharma is winning the big business popularity contest

By Nicole Wetsman

Memorials to honor COVID-19 dead begin to take shape

By Mary Beth Griggs
12 comments / new

The future of COVID-19 immunity looks good

By Nicole Wetsman

Time, money, and the new vaccination push

By Mary Beth Griggs
4 comments / new

Vaccine drives in the US are getting younger

By Mary Beth Griggs
4 comments / new

We may never know the exact toll of the pandemic

By Mary Beth Griggs
22 comments / new

New vaccine perks: halftime shots and savings bonds

By Mary Beth Griggs

The first problem was vaccine supply. Now, it’s demand. 

By Nicole Wetsman

On demand

For many, COVID-19 vaccines come with a side of side effects

Most reactions are mild — here’s what you need to know

By Mary Beth Griggs
83 comments / new

We’re on the knife’s edge of the pandemic

Antivirus: a weekly digest of COVID-19 research and development

By Mary Beth Griggs
46 comments / new

Vaccines are changing how we interpret COVID-19 numbers

By Nicole Wetsman

Welcome to the age of vaccine diplomacy

By Mary Beth Griggs
8 comments / new

Some research has gotten a huge boost during the pandemic

By Mary Beth Griggs
1 comment / new

COVID-19 vaccine supplies are on the rise in the US

By Mary Beth Griggs
7 comments / new

Vaccine centers embrace stickers and selfie stations 

By Mary Beth Griggs
5 comments / new

Stretched vaccine timelines re-enter the spotlight

By Mary Beth Griggs
7 comments / new

Vaccine rollout won’t be equitable unless health care reckons with racism

By Justine Calma

Why the FDA is taking 22 days to look over J&J’s data

By Mary Beth Griggs
18 comments / new

A good COVID-19 vaccine is good enough 

By Mary Beth Griggs
27 comments / new

A year into coronavirus, we’re still counting the dead

By Mary Beth Griggs
5 comments / new

CES showed off the COVID-19 mask gimmick arms race

By Nicole Wetsman

Mask madness

It’s 2021, and the pandemic is still here

No one wants 2021 to be 2020: The Sequel

By Mary Beth Griggs
11 comments / new

A COVID-19 vaccine gets a little bit extra

By Mary Beth Griggs
1 comment / new

We did the impossible thing, but not the hard thing

By Nicole Wetsman and Mary Beth Griggs
27 comments / new

Preparation for a big COVID-19 vaccine rollout is underway

By Mary Beth Griggs

Giving thanks during a pandemic

By Mary Beth Griggs

The COVID-19 pandemic hits new highs and new lows

By Mary Beth Griggs

A COVID tracing app misses the mark

By Mary Beth Griggs

A Swiss cheese approach to pandemic safety

By Mary Beth Griggs